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Table
Donor-recipient 8 HLA-allele match (N ¼ 70 units)
1 2 3 4 5 6 7 8 (N)
6/6 25% 25% 25% 25% 4
5/6 5% 19% 26% 35% 16% 43
4/6 13% 26% 26% 30% 4% 23
Pt# Age
(yrs)/
Sex
Donor Disease
status
CD34
dose/kg
(x106)
NK
dose/kg
Day of
NK cell
infusion
NK
associated
toxicity
1 23/M MRD CR3 4.65 1 x 106 23; 75 Grade 1
GVHD
2 24/M MUD CR3 5.14 1 x 105 24; 87 Grade 1
GVHD
3 25/F MRD CR3 8.69 1 x 106 23 None
4 18/M MRD CR2 4.88 1 x 106 22; 54 None
5 18/M MUD CR4 9.45 1 x 105 24 Too early
6 6/M MUD CR3 10 1 x 105 26 Too early
Disease status: CR¼complete remission #
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very high degree of donor-recipient HLA-allele mismatch,
the low TRM and relapse rates after pediatric DCBT are
striking, with either TBI-based or chemotherapy-only con-
ditioning. Although young children could have adequate
single-unit grafts, a signiﬁcant percentage will not. There-
fore, DCBT remains an important consideration, especially
for children of ethnic minorities.
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Background: Relapse is the primary cause of treatment
failure following allogeneic HCT. Preclinical data demon-
strates that large numbers of activated NK cells can be
generated ex vivo using artiﬁcial APCs (aAPC), that these
activated NK cells readily kill pediatric leukemia, and that
activity is independent of KIR mismatch. The post-transplant
period may be favorable for expansion and survival of
adoptively transferred NK cells potentially providing an
additional anti-leukemia effect.
Methods: We initiated a Phase I trial to assess safety and
feasibility of administration of escalating doses of donor-
derived activated NK cell infusions (NK-DLI) following mye-
loablative HLA-matched T-cell depleted PBSCT. Donors
underwent apheresis for ﬁlgrastim mobilized PBSC. The
product was T cell depleted and CD34/CD56 selected. The
CD56+ fractionwas cultured for 9e11 days with a K562 based
aAPC expressing 4-1BBL and IL-15Ra plus rhIL-15 to generate
the NK-DLI. T cell add back to the CD34 selected graft ranged
from 1-2 x 10e4 T cells/kg. NK-DLI was administered at days
21 and 49 (+/- 3 days) post-transplant. Patients received a
myeloablative preparative regimen (TBI 1200 cGy and
cyclophosphamide 60 mg/kg x 2 days). Recipients of unre-
lated donor products received GVHD prophylaxis with
tacrolimus and were dose escalated separately. The starting
dose for NK-DLI was 1 x 105 NK cells/kg for unrelated donor
recipients and 1 x 106 NK cells/kg for related donor
recipients.
Results: Six patients with high-risk ALL underwent trans-
plant (Table). The median time to neutrophil and platelet
engraftment was 9 and 12 days respectively. Median whole
blood and CD3 donor chimerism at day 28 was 91% (range,
49-100%) and 52% (range, 0-97%). Despite achieving primary
engraftment, one patient had absence of donor lymphoid
engraftment and underwent a second RIC T-replete HCT to
treat secondary rejection. Another subject received DLI to
treat mixed chimerism. Although persistence or engraftmentof infused NK-DLI cannot be deﬁnitely determined, in 5 of 6
recipients, the absolute NK value post-infusionwas a median
of 2.8 fold higher (range 1.7-4.3) than the pre-infusion value.
Two subjects had grade 1 GVHD. All subjects received the
second NK infusion off any immunosuppression. With
limited follow up, all patients remain disease free (2-12
months post-HCT).
Conclusions: Infusion of ex-vivo, aAPC expanded NK-DLI is
feasible and can be safely performed followingmyeloablative
allogeneic HCT in patients with high-risk leukemia. Accrual
and follow-up are ongoing.447
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Introduction: Unrelated donor (UD) attrition is a serious
problem impacting patients awaiting a transplant. In 2011
we presented results from a study of 7541 UD showing that
donor attrition at CT was 38.2% and signiﬁcantly worse in
women, ethnic minorities, non-blood donors and those be-
ing on the register longer.
Since then 3 signiﬁcant changes have been made: the
joining age was reduced to 16-30 (previously 18-40), the
maximum BMI allowed for PBSC donors was increased from
35 to 40 and an improved tracing system for uncontactable
donors was introduced.
The objective of this work was to assess the impact of
these changes on the proportion of donors involved in the
cancellation of requests.
Methods: All CT requests made from Anthony Nolan in 2013
were reviewed, and outcomes documented. For each request,
donor characteristics were documented.
Results: In 2013, 4207 requests were performed; 56.8% were
completed, while 37.7% were cancelled for donor reasons.
The univariate analysis showed that longer duration on the
register (p<0.001), not being a blood donor (p<0.001) and
African, African-Caribbean and Asian ethnicities (p<0.001)
were associated with higher attrition rates.
Compared to our previous study we found similar attri-
tion rates overall (38.2% to 37.7%; p¼0.6). However, therewas
a reduction in donor cancellations for medical reasons (30%
to 14.8%; p < 0.001). Conversely, we found that the attrition
rates due to emigration or travel had increased (7.9% to 13%;
p<0.001).
